Shanghai Henlius Biotech

Company

Last mentioned: Mar 24, 2026

Timeline

  1. 2025 Annual Results

    Fosun Pharma officially releases its full-year financial performance for 2025.

  2. US FDA Approval

    Key biosimilar assets receive final marketing authorization for the US market.

  3. CAR-T Expansion

    Yescarta receives expanded indication approval for second-line treatment in China.

  4. ADC Platform Milestone

    First internally developed ADC candidate enters Phase II clinical trials.

Stories mentioning Shanghai Henlius Biotech 1

pharma Neutral

Fosun Pharma 2025 Results: Innovation Revenue Surges as Global Footprint Expands

Fosun Pharma (2196.HK) reported its 2025 annual results, highlighting a significant shift toward innovative drug revenue and successful international commercialization of its biosimilar portfolio. The company's strategic focus on oncology and high-value therapeutics continues to drive growth despite a challenging global macroeconomic environment.

2 sources